VERU INC. - COMMON STOCK

Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia

13 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

08 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Veru Reports Record Fiscal 2021 Full-Year Financial Results

02 Dec 2021 05:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd

18 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Veru to Participate in Fireside Chat at the Jefferies London Healthcare Conference on November 16-18, 2021

08 Nov 2021 07:30:01 By Nasdaq GlobeNewswire

Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer

13 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

20 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

09 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Veru to Present at Three Upcoming Healthcare Investment Conferences

08 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter

12 Aug 2021 05:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th

29 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress

28 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer

25 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer

10 Jun 2021 07:30:01 By Nasdaq GlobeNewswire

Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting

07 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting

07 Jun 2021 07:15:00 By Nasdaq GlobeNewswire

Veru to Present at the Jefferies Virtual Healthcare Conference

25 May 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

24 May 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients

19 May 2021 07:30:00 By Nasdaq GlobeNewswire

Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues

12 May 2021 05:30:00 By Nasdaq GlobeNewswire